HUP0002392A2 - Növekedési hormon kiválasztását fokozó diazol-, oxazolszármazékok, eljárás előállításukra, valamint ezeket tartalmazó gyógyászati készítmények - Google Patents

Növekedési hormon kiválasztását fokozó diazol-, oxazolszármazékok, eljárás előállításukra, valamint ezeket tartalmazó gyógyászati készítmények

Info

Publication number
HUP0002392A2
HUP0002392A2 HU0002392A HUP0002392A HUP0002392A2 HU P0002392 A2 HUP0002392 A2 HU P0002392A2 HU 0002392 A HU0002392 A HU 0002392A HU P0002392 A HUP0002392 A HU P0002392A HU P0002392 A2 HUP0002392 A2 HU P0002392A2
Authority
HU
Hungary
Prior art keywords
alkyl
aryl
alkylaryl
ylalkyl
naphthyl
Prior art date
Application number
HU0002392A
Other languages
English (en)
Inventor
Charles Arthur Alt
Henry Uhlman Bryant
Jeffrey Daniel Cohen
James Densmore Copp
Jeffrey Alan Dodge
Kennan Joseph Fahey
William Harlan Gritton
Kenneth Lee Hauser
Mark Louis Heiman
Scott Alan Jones
Louis Nickolaus Jungheim
Joseph Henry Kennedy
Charles Willis Lugar III.
Brian Stephen Muehl
Alan David Palkowitz
Andrew Michael Ratz
Gary Anthony Rhodes
Robert Lewis Robey
David Edward Seyler
Timothy Alan Shepherd
Kenneth Jeff Thrasher
William George Trankle
Original Assignee
Eli Lilly And Co.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eli Lilly And Co. filed Critical Eli Lilly And Co.
Publication of HUP0002392A2 publication Critical patent/HUP0002392A2/hu
Publication of HUP0002392A3 publication Critical patent/HUP0002392A3/hu

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06026—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atom, i.e. Gly or Ala
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/36—Oxygen or sulfur atoms
    • C07D207/40—2,5-Pyrrolidine-diones
    • C07D207/416—2,5-Pyrrolidine-diones with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to other ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
    • A61P5/04—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin for decreasing, blocking or antagonising the activity of the hypothalamic hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/16—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/42—Nitro radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/38—Nitrogen atoms
    • C07D231/40—Acylated on said nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/88—Nitrogen atoms, e.g. allantoin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/0606—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing heteroatoms not provided for by C07K5/06086 - C07K5/06139, e.g. Ser, Met, Cys, Thr

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Steroid Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

A találmány tárgyát az (I) általános képletű vegyületek, e vegyületekgyógyászatilag megfelelő sói vagy szolvátjai, valamint ezekettartalmazó gyógyászati készítmények képezik. A találmány tárgyáhoztartozik ezen kívül az (I) általános képletű vegyületek előállításáraszolgáló eljárás is. A találmány szerinti vegyületek kedvezőenbefolyásolják a növekedési hormonszintet. Az (I) általános képletben aszubsztituensek jelentése igen sokféle, többek között A jelentése alkil-, aril-, alkil-aril-, alkil-(O)-alkil-aril-, alkil-(S)-alkil-aril-, indolil-, indolinil-, tienil-, alkil-tienil-,benzotienil-, benzofuranil-, naftil-, ciklohexil-, alkil-indolil-,alkil-benzotienil-, alkil-naftil-, alkil-benzofuranil- vagy alkil-ciklohexil-csoport; B jelentése -NH2, -NHR1, alkil-NH2, alkil-NHR1, alkil-aril-NH2, alkil-aril-NHR1, alkil-ciklohexil-NH2, alkil-ciklohexil-NH-R1, R1-piperidin-3-il-alkil-, R1-piperidin-2-il-alkil-, R1-piperidin-4-il-alkil-, R1-kinolin-2-il-alkil-, R1-(2,4-dihidrokinolin-2-il-alkil-, R1-izokinolin-2-il-alkil- vagy R1-(2,4-dihidroizokinolin-2-il)-alkil-csoport; X jelentése alkilidenil-, O, S, NH- vagy N-alkil-csoport; V jelentése heterociklusos csoport, D jelentése hidrogénatom, alkil-, alkil-(O)(CO)-alkil-, alkil-(O)(CO)N-(alkil)2-, alkil-aril-, C(O)R6, alkil-(O)-R6, alkil-(OH)-,alkil-C(O)-R6, alkil-R6, aril-, alkil-NHSO2-alkil-, alkil)-NHSO2-arilcsoport; E jelentése hidrogénatom, alkil-, C(O)-alkil-, aril-, (aril)-C(O)NR6,aril-alkil-C(O)R6, alkil-aril-, C(O)-aril-, alkil-C(O)-aril-, naftil-,alkil-naftil, C(O)-naftil-, alkil-C(O)-naftil-, heteroaril-, alkil-heteroaril-, C(O)-heteroaril-, alkil-C(O)-heteroaril-, indanil-,alkil-indanil-, C(O)-indanil-, -C(O)-indanil- vagy cikloalkilcsoort; G jelentése hidrogénatom, alkil-, aril-, alkil-aril- vagyalkenilcsoport; J jelentése hidrogénatom, alkil-, aril- vagy alkil-aril-csoport; L jelentése hidrogénatom, alkil-, C(O)O-alkil-, aril-, alkil-aril-,C(O)O-alkil-aril-, alkenil-, -F vagy -CN, alkil-OH, alkil-O-alkil-,alkil-C(O)R6 képletű csoport. Ó
HU0002392A 1997-08-19 1998-08-19 Diazole and oxazole derivatives as growth hormone secretagogues, process for producing them and pharmaceutical compositions containing them HUP0002392A3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US5614297P 1997-08-19 1997-08-19
PCT/US1998/017229 WO1999008699A1 (en) 1997-08-19 1998-08-19 Growth hormone secretagogues

Publications (2)

Publication Number Publication Date
HUP0002392A2 true HUP0002392A2 (hu) 2000-10-28
HUP0002392A3 HUP0002392A3 (en) 2000-11-28

Family

ID=22002443

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0002392A HUP0002392A3 (en) 1997-08-19 1998-08-19 Diazole and oxazole derivatives as growth hormone secretagogues, process for producing them and pharmaceutical compositions containing them

Country Status (24)

Country Link
EP (1) EP0933365A3 (hu)
JP (1) JP2001515046A (hu)
KR (1) KR20010027947A (hu)
CN (1) CN1243567C (hu)
AR (1) AR018010A1 (hu)
AU (1) AU738204B2 (hu)
BR (1) BR9811948A (hu)
CA (1) CA2302467A1 (hu)
CO (1) CO5121066A1 (hu)
EA (1) EA002746B1 (hu)
HR (1) HRP20000090A2 (hu)
HU (1) HUP0002392A3 (hu)
ID (1) ID25000A (hu)
IL (1) IL134596A0 (hu)
MY (1) MY138258A (hu)
NO (1) NO20000823L (hu)
NZ (1) NZ502947A (hu)
PE (1) PE115999A1 (hu)
PL (1) PL338883A1 (hu)
TR (1) TR200000930T2 (hu)
TW (1) TW577879B (hu)
UA (1) UA58472C2 (hu)
WO (1) WO1999008699A1 (hu)
ZA (1) ZA987385B (hu)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6639076B1 (en) 1998-08-18 2003-10-28 Eli Lilly And Company Growth hormone secretagogues
AU2686899A (en) * 1998-08-18 2000-03-14 Eli Lilly And Company Growth hormone secretagogues
US6828331B1 (en) 1999-02-19 2004-12-07 Eli Lilly And Company Growth hormone secretagogues
CO5160260A1 (es) * 1999-02-19 2002-05-30 Lilly Co Eli Secretagogos de la hormona del crecimiento derivados de imi- dazol 1,4- substituido
US6417397B1 (en) 1999-10-04 2002-07-09 The Regents Of The University Of California, San Diego N-substituted alkylamino acids for use as amino-protecting groups
EP1289526A4 (en) 2000-05-30 2005-03-16 Merck & Co Inc MELANOCORTIN RECEPTOR AGONISTS
GT200100147A (es) * 2000-07-31 2002-06-25 Derivados de imidazol
US6756385B2 (en) * 2000-07-31 2004-06-29 Pfizer Inc. Imidazole derivatives
AU2001294532A1 (en) * 2000-10-13 2002-04-29 Eli Lilly And Company Resolution process for preparation of substantially pure (r) and (s) enantiomersof 2-(4-nitroimidazolyl)-4-methoxyphenylpropionic acid and salts thereof
US7125840B2 (en) 2001-10-09 2006-10-24 Eli Lilly And Company Substituted dipeptides as growth hormone secretagogues
DE60306636T2 (de) 2002-04-09 2007-07-05 Eli Lilly And Co., Indianapolis Wachstumhormonsekretionsförderer
US7365082B2 (en) * 2002-12-18 2008-04-29 Bayer Cropscience Ag N-(substituted arylmethyl)-4-(disubstituted methyl)piperidines and piperazines
CN1934091B (zh) 2004-03-23 2012-02-08 辉瑞产品公司 治疗神经变性障碍的咪唑化合物
JP2009508934A (ja) 2005-09-22 2009-03-05 ファイザー・プロダクツ・インク 神経障害治療のためのイミダゾール化合物
US7601844B2 (en) 2006-01-27 2009-10-13 Bristol-Myers Squibb Company Piperidinyl derivatives as modulators of chemokine receptor activity
US7615556B2 (en) 2006-01-27 2009-11-10 Bristol-Myers Squibb Company Piperazinyl derivatives as modulators of chemokine receptor activity
ES2602789T3 (es) 2007-02-09 2017-02-22 Ocera Therapeutics, Inc. Productos intermedios conectores para la síntesis de moduladores macrocíclicos del receptor de la grelina
TWI433838B (zh) 2008-06-25 2014-04-11 必治妥美雅史谷比公司 作為趨化因子受體活性調節劑之六氫吡啶衍生物
US8642622B2 (en) 2010-06-16 2014-02-04 Bristol-Myers Squibb Company Piperidinyl compound as a modulator of chemokine receptor activity
US8546416B2 (en) 2011-05-27 2013-10-01 Novartis Ag 3-spirocyclic piperidine derivatives as ghrelin receptor agonists
JP2015525202A (ja) 2012-05-03 2015-09-03 ノバルティス アーゲー グレリン受容体アゴニストとしての２，７−ジアザ−スピロ［４，５］デカ−７−イル誘導体のｌ−リンゴ酸塩およびその結晶形態
PL3022202T3 (pl) 2013-07-18 2019-10-31 Novartis Ag Inhibitory autotaksyny zawierające heteroaromatyczny rdzeń pierścienia benzylowego - cyklicznego amidu
US9119832B2 (en) 2014-02-05 2015-09-01 The Regents Of The University Of California Methods of treating mild brain injury
RU2692774C2 (ru) 2014-08-29 2019-06-27 Дайсел Корпорэйшн Имидазольное соединение, жидкость для обработки металлической поверхности, способ обработки металлической поверхности и способ изготовления ламината
WO2017075535A1 (en) 2015-10-28 2017-05-04 Oxeia Biopharmaceuticals, Inc. Methods of treating neurodegenerative conditions
CN107286041A (zh) * 2016-04-01 2017-10-24 成都川科化工有限公司 一种n,n-二乙基甲酰胺的制备方法
CN108299218A (zh) * 2017-01-12 2018-07-20 南京红杉生物科技有限公司 一种4-溴-d-苯丙氨酸的合成方法
CN110128285B (zh) * 2019-06-24 2022-03-01 华北制药股份有限公司 D-苯甘氨酸甲酯盐酸盐/d-二氢苯基甘氨酸甲酯盐酸盐的制备方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5206235A (en) * 1991-03-20 1993-04-27 Merck & Co., Inc. Benzo-fused lactams that promote the release of growth hormone
WO1994013696A1 (en) * 1992-12-11 1994-06-23 Merck & Co., Inc. Spiro piperidines and homologs which promote release of growth hormone
PL314003A1 (en) * 1993-10-19 1996-08-05 Merck & Co Inc Combination of bisulphonates and substances enhancing secretion of growth hormone
US5492916A (en) * 1993-12-23 1996-02-20 Merck & Co., Inc. Di- and tri-substituted piperidines, pyrrolidines and hexahydro-1H-azepines promote release of growth hormone
US5798337A (en) * 1994-11-16 1998-08-25 Genentech, Inc. Low molecular weight peptidomimetic growth hormone secretagogues
ZA966891B (en) * 1995-08-21 1998-02-16 Lilly Co Eli 2-acylaminopropanamines as growth hormone secretagogues.
WO1997006803A1 (en) * 1995-08-21 1997-02-27 Eli Lilly And Company 2-acylaminopropanamides as growth hormone secretagogues

Also Published As

Publication number Publication date
MY138258A (en) 2009-05-29
CO5121066A1 (es) 2002-01-30
CN1276727A (zh) 2000-12-13
KR20010027947A (ko) 2001-04-06
HRP20000090A2 (en) 2001-04-30
NO20000823D0 (no) 2000-02-18
TW577879B (en) 2004-03-01
AR018010A1 (es) 2001-10-31
NZ502947A (en) 2001-11-30
AU738204B2 (en) 2001-09-13
CA2302467A1 (en) 1999-02-25
AU9025698A (en) 1999-03-08
ZA987385B (en) 2000-04-18
NO20000823L (no) 2000-04-12
HUP0002392A3 (en) 2000-11-28
EP0933365A3 (en) 2003-03-19
JP2001515046A (ja) 2001-09-18
PE115999A1 (es) 1999-11-26
CN1243567C (zh) 2006-03-01
BR9811948A (pt) 2000-08-22
TR200000930T2 (tr) 2000-11-21
IL134596A0 (en) 2001-04-30
UA58472C2 (uk) 2003-08-15
PL338883A1 (en) 2000-11-20
EA002746B1 (ru) 2002-08-29
EP0933365A2 (en) 1999-08-04
EA200000239A1 (ru) 2000-10-30
ID25000A (id) 2000-09-07
WO1999008699A1 (en) 1999-02-25

Similar Documents

Publication Publication Date Title
HUP0002392A2 (hu) Növekedési hormon kiválasztását fokozó diazol-, oxazolszármazékok, eljárás előállításukra, valamint ezeket tartalmazó gyógyászati készítmények
HUP9901079A2 (hu) 5- és 6-Tagú nitrogéntartalmú gyűrűs vegyületek, eljárás előállításukra és ezeket tartalmazó gyógyszerkészítmények
HUP0000434A2 (hu) 1,4-Szubsztituált gyűrűs aminszármazékok
UA39093C2 (uk) Похідні пептидів, що є інгібіторами еластази лейкоцитів людини, спосіб їх отримання та фармацевтична композиція
HUP0100579A2 (hu) Amino-vajsav-származékok és ezeket tartalmazó gyógyszerkészítmények
HUP0003309A2 (hu) Imidazolilcsoportot tartalmazó gyűrűs acetálok, eljárás előállításukra és az ezeket tartalmazó gyógyszerkészítmények
YU46819B (sh) Postupak za dobijanje norstatina i nor-ciklostatinanje norstatina i norciklostati
HU9603185D0 (en) New azolidinediones as antihyperglycemic agents
ES8601156A1 (es) Un procedimiento para preparar derivados de carboximida
EP0829474A4 (en) INDAZOLE DERIVATIVES WITH A CYCLIC AMINO GROUP
HUT72434A (en) Novel pyridone carboxylic acid derivatives, pharmaceutical compositions containing them and processes for their production
HUT65943A (en) Process for producing benzothiazolylmethyl- and pyperazinomethyl-2,4,6-cycloheptatriene-1-one derivatives and pharmaceutical preparations containing them
ATE131030T1 (de) Indolin-produkte, ihren verfahren zu deren herstellung sowie ihren verwendung in der kosmetik.
HUP9900913A2 (hu) Eljárás N-monoszubsztituált és N,N'-diszubsztituált aszimmetrikus 7-tagú ciklusos karbamidok előállítására
NO963949D0 (no) Amidderivater av vitamin D
DK0408760T3 (da) Hydroxylaminderivater
MX9707427A (es) Nuevos taxoides, su preparacion y las composiciones farmaceuticas que los contienen.
ZA984114B (en) Substituted heterocyclic compounds a process for the preparation thereof and pharmaceutical compositions containing them
HUP0102522A2 (hu) 3',3'-N-bisz-helyettesített makrolid LHRH antagonista vegyületek és alkalmazásuk, eljárás előállításukra, valamint e vegyületeket tartalmazó gyógyászati készítmények
DE60104986D1 (de) Xanthinderivate, zwischenprodukte und verwendung zur behandlung von osteoporosis
HUP0105111A1 (hu) 2,5-Helyettesített benzolszulfonilkarbamid- és tiokarbamidszármazékok, eljárás előállításukra, alkalmazásuk, valamint e vegyületeket tartalmazó gyógyászati készítmények
GB1397624A (en) Composition ror oral administration for counteracting the greasy appearance of the head of hair and or the skin
ES8307734A1 (es) "procedimiento de producir derivados amidicos".
DE59304826D1 (de) Substituierte 3-azabicyclo[3.2.0]heptan-derivate als zwischenprodukte
NZ336585A (en) 2,6-dimethyl-4-(3-nitro-phenyl)-5-methoxycarbonyl-1,4-dihydropyridine-3-carboxylate derivatives substituted by N-[5-(1H-2-pyrrolyl)-5-oxopentyl] or [4-(2-thienoyl or 2,4,6-trimethoxybenzoyl)-butyl]-pyrrolid-3-ine or piperid-3-ine